A detailed history of American Portfolios Advisors transactions in Regenxbio Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 25 shares of RGNX stock, worth $262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25
Holding current value
$262
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$22.29 - $35.04 $557 - $876
25 New
25 $661,000
Q1 2020

Mar 24, 2023

BUY
$21.5 - $54.2 $1,075 - $2,710
50 Added 200.0%
75 $2.43 Million
Q4 2019

Mar 24, 2023

BUY
$34.54 - $44.87 $5,181 - $6,730
150 Added 600.0%
175 $7.17 Million
Q3 2019

Mar 24, 2023

SELL
$31.84 - $50.88 $955 - $1,526
-30 Reduced 14.63%
175 $6.23 Million
Q2 2019

Mar 24, 2023

BUY
$42.0 - $59.29 $7,560 - $10,672
180 Added 720.0%
205 $10.5 Million
Q1 2019

Mar 24, 2023

BUY
$40.82 - $62.45 $1,836 - $2,810
45 Added 90.0%
95 $5.44 Million
Q4 2018

Mar 24, 2023

BUY
$39.11 - $75.15 $977 - $1,878
25 Added 100.0%
50 $2.1 Million

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $453M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.